A GSK manager said that bringing digital devices to clinical trials could lower the cost of bringing medicines to patients.
An analysis conducted by J&J executives found that 58% of FDA warning letters and untitled letters over the last two years omitted risk information.
The drugmaker launched its first YouTube channel as it kicked off the campaign.
By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.
There remains a pressing need for more progress in puncturing the glass ceiling